• Ghazaleh Khalili-Tanha, Nima Khalili-Tanha, Arian Karimi Rouzbahani, Ramisa Mahdieh, Kimia Jasemi, Rosa Ghaderi, Fatemeh Khojasteh Leylakoohi, Elnaz Ghorbani, Majid Khazaei, Seyed Mahdi Hassanian, Ibrahim Saeed Gataa, Gordon A Ferns, Elham Nazari, and Amir Avan.
• Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
• Transl Res. 2024 Dec 1; 274: 354835-48.

AbstractGastric cancer is a major health concern worldwide. The survival rate of Gastric cancer greatly depends on the stage at which it is diagnosed. Early diagnosis is critical for improving survival outcomes. To improve the chances of early diagnosis, regular screening tests, such as an upper endoscopy or barium swallow, are recommended for individuals at a higher risk due to factors like family history or a previous diagnosis of gastric conditions. Biomarkers can be detected and measured using non-invasive methods such as blood tests, urine tests, breath analysis, or imaging techniques. These non-invasive approaches offer many advantages, including convenience, safety, and cost-effectiveness, making them valuable tools for disease diagnosis, monitoring, and research. Biomarker-based tests have emerged as a useful tool for identifying gastric cancer early, monitoring treatment response, assessing the recurrence risk, and personalizing treatment plans. In this current review, we have explored both classical and novel biomarkers for gastric cancer. We have centralized their potential clinical application and discussed the challenges in Gastric cancer research.Copyright © 2024. Published by Elsevier Inc.

11 keywords...

hide…